摘要：目的探究噻托溴铵联合沙美特罗丙酸氟替卡松治疗老年(稳定期)慢性阻塞性肺病的临床效果。方法噻托溴铵联合沙美特罗丙酸氟替卡松组(A组)患者给予吸入噻托溴铵干粉剂与沙美特罗丙酸氟替卡松；噻托溴铵组(B组)患者给予吸入噻托溴铵干粉剂；沙美特罗丙酸氟替卡松组(C组)患者给予吸入沙美特罗丙酸氟替卡松，分别在治疗前及治疗后3个月时测定老年(稳定期)慢性阻塞性肺病患者肺功能。结果治疗3个月后，与B、C组相比，A组第1s用力呼气量(FEV1)与用力肺活量(FVC)显著提高，具有统计学意义(P<0.05)；B组与C组相比用力呼气量(FEV1)与用力肺活量(FVC)差异不显著(P>0.05)。结果两种药物联合应用支气管扩张作用更加显著，有利于改善老年(稳定期)慢性阻塞性肺病患者的肺功能，值得临床推广使用。

    关键词：慢性阻塞性肺病；噻托溴铵；沙美特罗丙酸氟替卡松；临床效果分析

    Therapeutic Effect Analysis of Salmeterol/Fluticasone Propionate Combined with Tiotropium Bromide Therapy for Elderly Patients with COPD

    JIANG Yu-shun

    (Hezhou City People's Hospital,Hezhou 542899,Guangxi,China)

    Abstract：ObjectiveTo explore the therapeutic effect of chronic obstructive pulmonary disease (COPD) combination with tiotropium bromide powder for Inhalation (Spiriva) and Salmeterol/Fluticasone. MethodsThe combined treatment group (group A) was given tiotropium bromide dry powder and Salmeterol/Fluticasone Propionate; tiotropium bromide group (group B) was given tiotropium bromide dry powder; Salmeterol/Fluticasone Propionate group (group C) was given Salmeterol/Fluticasone Propionate. Lung functions were compared in the three groups before and after the treatment three months later. Results Compared with tiotropium bromide group and Salmeterol/Fluticasone Propionate group, the FEV1 and FVC of the combined group improved remarkable (P<0.05) on three months later; the improvement between tiotropium bromide group and Salmeterol/Fluticasone Propionate group have no significant differences (P>0.05). Conclusion Combination of three kinds of medications has stronger bronchiectasis effect, which can significantly improve lung function of COPD patients. It is worthy of clinical use. ......